Heights

Heights is a UK-based health company specializing in science-backed supplements that enhance brain function and gut health, offering consumers high-impact nutritional solutions for overall wellness. Founded in 2019 in London, UK, Heights focuses on creating innovative health supplements. The company has successfully closed one deal and raised a total of GBP 2 million in venture funding, which values the firm at GBP 60 million post money. Their latest funding round occurred in December 2025.

Heights specializes in science-backed supplements designed to enhance brain function and gut health, focusing on delivering high-impact ingredients that promote overall wellness. Their core product offerings include Vitals⁺, which provides 20 essential nutrients to fuel the body and brain; Biotic⁺, formulated with seven high-impact bacteria strains plus zinc to support gut health; and Magnesium⁺, which utilizes magnesium glycinate to support over 300 bodily functions. These products aim to address common health concerns such as sleep quality, cognitive performance, and digestive health, thereby improving daily energy levels and overall well-being. Heights primarily serves individual consumers, including health-conscious adults seeking to optimize their nutrition without the hassle of multiple supplements.

The company's supplements are available in various international markets, including the United States and the United Kingdom, allowing them to reach a diverse customer base. Heights generates revenue through direct-to-consumer sales primarily via subscription models, allowing customers to receive their products regularly at set intervals. The company structures its pricing plans around its flagship products, with Vitals⁺ priced at USD 48 for a 30-day supply, Biotic⁺ also at USD 48 for the same duration, and Magnesium⁺ at USD 27. This subscription approach not only facilitates consistent revenue flow but also enhances customer retention by encouraging long-term health habits.

Additionally, Heights offers bundles that provide customers with a combination of products at a discounted rate, further incentivizing purchases and enhancing value. Overall, the revenue model is designed to cater to the increasing demand for convenient, high-quality health supplements in both domestic and international markets. In December 2025, Heights raised GBP 2 million in venture funding from unspecified investors, which will be utilized to support the introduction of new product lines and geographic expansion plans. The company aims to launch additional supplements in the coming year, targeting markets in Europe and Asia by 2026.

The recent funding will support these initiatives by enhancing research and development efforts as well as expanding marketing activities.